Qualify for a free subscription to HealthLeaders magazine.
Technology: The iPill
Manufacturer: Royal Philips Electronics of the Netherlands
Purpose: Intelligent pill technology is targeted at assisting drug development and enabling new therapies for debilitating and life-threatening digestive tract disorders such as Crohn's disease, colitis, and colon cancer.
Early adopter: Still in prototype form.
How it works: The iPill is a capsule about the size of a multivitamin that has been designed to be swallowed and pass through the digestive track naturally. It can be electronically programmed to control the delivery of medicine according to a predefined drug release profile. The iPill releases medicine from its drug reservoir via a microprocessor-controlled pump, allowing accurate programmable drug delivery.
Potential Improvement: The iPill's developers say the combination of navigational feedback, electronically controlled drug delivery, and monitoring of the intestinal tract offer the potential to improve drug candidate profiling and selection, which, they say, could ultimately accelerate the development of new drugs.
What's Next: Philips will begin testing the iPill in animals and is consulting with pharmaceutical companies to evaluate what drugs might work best with it.
- Hospital Groups Strike Back at Hospital Rating Systems
- 5 Hot Healthcare Ideas from SXSW
- AHIP: Enormity of HIX Challenges Sinks In
- The Secret to Physician Engagement? It's Not Better Pay
- Hospital CEO Turnover Hits Record High
- Another SGR Patch Likely, Lawmaker Says
- Rules to Rein in HIX Narrow Networks Could Drive Away Payers
- How Succession Planning Boosts Employee Retention Rates
- 4 Reasons PCMH Principles Aren't Going Away
- Two-Midnight Rule Must be Fixed or Replaced, Say Providers